Thursday, November 19, 2026
Katherine Stapp
- The company that mapped the human genome is joining efforts to unravel the DNA of the primary mosquito that carries malaria, in hopes of developing a vaccine or better drugs against a scourge that kills millions each year.
U.S.-based Celera Genomics Group has won a nine million dollar grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health – once Celera’s public-sector rival in the race to sequence the human genome.
The grant will help the private-sector firm sequence the genome of the Anopheles gambiae mosquito, with results expected by next spring. The data will be analysed in conjunction with ongoing efforts to sequence the genome of the deadliest malaria parasite, Plasmodium falciparum, and the already completed human genome.
“This initiative will give us the pieces to an incredibly complex puzzle,” said NIAID director Anthony Fauci. “By analysing and comparing the genomes of all three organisms, researchers will have a wealth of new information for understanding malaria and how it is spread, and for use in developing new tools to help reduce its devastating impact.”
Foremost among these tools would be an effective vaccine, for which scientists have been searching since the 1960s.
The grant to Celera supplements more than two years of research into the Anopheles mosquito genome by an international consortium that includes the World Health Organisation, the Pasteur Institute’s sequencing centre Genoscope, the European Molecular Biology Laboratory, and others.
In genetic sequencing, scientists map the paired chemical bases on an organism’s DNA strand represented by the letters A, C, G, and T, most of which encode genes. While the human genome contains three billion base pairs of DNA, a bacterium’s genome typically contains just one million to four million base pairs.
Once the genome has been sequenced, computers, robotics, and other advanced technologies assist scientists in annotating and analysing the data – essentially, predicting the position and function of each gene.
Malaria is caused by the single-celled Plasmodium parasite. While there are four species that can infect humans, the deadliest is the Plasmodium falciparum, which is rampant in Sub-Saharan Africa. It is spread through the bite of mosquitoes.
To give a picture of how bad the situation is in some parts of Africa, a recent paper by John Luke Gallup and Jeffrey D. Sachs of Harvard University’s Centre for International Development relates a brief history of malaria eradication efforts sponsored in Garki, Nigeria in the 1960s by the World Health Organisation.
During the rainy season, a person living in Garki district would be bitten an average of 174 times per night by Anopheles gambiae and 94 times per night by Anopheles funestus mosquitoes.
“No resources, manpower or institutional support were spared” in spraying huts with insecticide and administering anti-malarial drugs, Gallup and Sachs write. Yet, “there was no significant change in the parasite rate among the villagers.”
In simple terms, there were so many mosquitoes that even reducing their contact with humans by 90 percent made little difference. People were still being bitten.
“Malaria control in sub-Saharan Africa has been a non-starter,” Gallup and Sachs conclude.
Thus, scientists argue, a vaccine or an entirely new angle of attack, perhaps at the genetic level, is needed to cope with the parasite in this region.
Symptoms of malaria include high fever, anaemia, chills, and vomiting. More than 15 percent of those who survive malarial attacks are left with severe neurological damage and impaired function.
Until recently, it was assumed that malaria killed about one million people a year, mostly in Africa. But new research from the Multilateral Initiative on Malaria, an umbrella group of governments, international organisations and private foundations, has uncovered a drastic underestimation of mortality and morbidity rates. It said these are likely closer to three million dead per year and nearly one billion acute febrile attacks, more than three- quarters of which occur among African children.
The research, published earlier this year in the American Journal of Tropical Medicine and Hygiene, emphasised that malaria is as much a cause of poverty as a consequence. It estimates that the malaria parasite is costing Africa up to 12 billion dollars in lost productivity per year.
“To address the pervasive and intractable problems that malaria represents, it is essential that malaria’s full burden on societies and families be measured both epidemiologically and economically,” said Gerald D. Keusch, head of the Multilateral Initiative on Malaria.
The estimate of one million deaths yearly relied heavily on infant mortality data that was 30-40 years old, Keusch explained. “The whole idea of having a more accurate disease burden assessment is to be able to track the ability of programmes to effectively address that burden,” he said.
Malaria is notoriously hard to control in endemic regions like Africa. The parasite has developed resistance to mainstay treatment drugs like chloroquine and the mosquitoes that carry it have evolved resistance to pesticides like DDT.
Once a cornerstone of malaria prevention efforts, DDT later fell out of favour for its adverse impact on wildlife. It is now being used again in hard-hit places like South Africa due to the lack of viable alternatives.
“DDT is still the cheapest, most effective and, if used appropriately, the safest way of controlling mosquito transmissions in and around households,” Keusch said. “We have to separate the public health and agricultural uses of DDT. There’s really nothing else that’s as affordable.”
The NIAID is also supporting research to sequence and annotate the genomes of 13 other disease-carrying bacteria, including tuberculosis, gonorrhea, chlamydia, and cholera.
The database of the malaria sequencing project will be made available to researchers worldwide via the Internet.